Leerink Partners Reiterates Outperform Following Globus Medical's (GMED) Strong 4Q
Tweet Send to a Friend
Leerink Partners maintained an Outperform rating on Globus Medical (NYSE: GMED), and cut the price target to $29.00 (from $32.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
